Recently, the Greater China Cancer Foundation (GCCF) held a significant meeting to discuss the development strategy for cell and gene therapy (CGT) in Hong Kong. Attendees included: Dr. Cheng Kam-chung (JP), Chairman of the GCCF; foundation members Dr. Lau Cho-chiu, Counselor Yeung Kin-chung, and Council Member Liao Lingling; Prof. Chan Chi-fung, Consultant Pediatrician at the University of Hong Kong; Dr. Cheuk Ka-leung, Head of Cell Therapy at Hong Kong Children's Hospital; Prof. Ronald Li, Founder of Xellera Therapeutics Limited, and its CEO, Dr. Camie Chan; as well as Mr. Ng Lok-man, Director of Patient Advocacy and Public Affairs at Medical Reasoning (Yi Li Shuo).Additionally,Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley Biomedical Co., Ltd., together with Dr. Fu Yuchen, Chairman’s Assistant, was invited to attend the meeting as a caring partner of the Foundation.

The meeting focused on advancing the development of Cell and Gene Therapy (CGT) in Hong Kong. Participants engaged in in-depth exchanges and active discussions. In this cutting-edge field of CGT, all parties demonstrated a strong willingness to collaborate and a high sense of responsibility. They are committed to leveraging the geographical advantages of Shenzhen and Hong Kong, integrating resources from both cities, and fostering collaborative innovation. The ultimate goal is to accelerate the implementation and application of CGT technologies in Hong Kong, thereby enhancing the region's medical standards and providing robust support for improving patients' quality of life.